News | February 27, 2026
Novo Nordisk slashes prices of Wegovy & Ozempic by up to 50%
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
The NDA filing is supported by results from the phase III evERA Breast Cancer study
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose
Subscribe To Our Newsletter & Stay Updated
